After ataxia withdrawal, Santhera considers strategic moves
This article was originally published in Scrip
Executive Summary
Just a day after announcing the voluntary withdrawal of Catena (idebenone) from Canada where it was conditionally approved for Friedreich’s Ataxia, Swiss firm Santhera said its board has decided to 'consider strategic options' including the possibility of a merger or acquisition.